169 related articles for article (PubMed ID: 20943618)
1. Optimal treatment for relapsing ovarian cancer.
Ledermann JA; Kristeleit RS
Ann Oncol; 2010 Oct; 21 Suppl 7():vii218-22. PubMed ID: 20943618
[TBL] [Abstract][Full Text] [Related]
2. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
Monk BJ; Coleman RL
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S63-7. PubMed ID: 19955917
[TBL] [Abstract][Full Text] [Related]
3. Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer.
Ledermann JA; Raja FA
Eur J Cancer; 2011 Sep; 47 Suppl 3():S104-15. PubMed ID: 21943964
[TBL] [Abstract][Full Text] [Related]
4. Copy number variations of neurotrophic tyrosine receptor kinase 3 (NTRK3) may predict prognosis of ovarian cancer.
Ge L; Li N; Liu M; Xu NZ; Wang MR; Wu LY
Medicine (Baltimore); 2017 Jul; 96(30):e7621. PubMed ID: 28746220
[TBL] [Abstract][Full Text] [Related]
5. Optimal management of recurrent ovarian cancer.
Markman M
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S40-3. PubMed ID: 19955913
[TBL] [Abstract][Full Text] [Related]
6. Emerging therapeutic options for platinum-sensitive ovarian cancer patients.
Armstrong DK; Coleman RL; Penson RT
Clin Adv Hematol Oncol; 2011 Apr; 9(4 Suppl 5):1-16. PubMed ID: 21558997
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
8. The current treatment of recurrent ovarian cancer.
Herzog TJ
Curr Oncol Rep; 2006 Nov; 8(6):448-54. PubMed ID: 17040623
[TBL] [Abstract][Full Text] [Related]
9. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
10. Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.
Modesitt SC; Jazaeri AA
Expert Opin Pharmacother; 2007 Oct; 8(14):2293-305. PubMed ID: 17927484
[TBL] [Abstract][Full Text] [Related]
11. Therapy for recurrent ovarian cancer.
Kuhn WC
Curr Womens Health Rep; 2003 Feb; 3(1):33-8. PubMed ID: 12521548
[TBL] [Abstract][Full Text] [Related]
12. [Not Available].
Floquet A; Berton-Rigaud D; Ferron G; Freyer G; Hardy-Bessard AC; You B
Bull Cancer; 2017 May; 104 Suppl 1():S24-S31. PubMed ID: 28625312
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.
Noonan AM; Bunch KP; Chen JQ; Herrmann MA; Lee JM; Kohn EC; O'Sullivan CC; Jordan E; Houston N; Takebe N; Kinders RJ; Cao L; Peer CJ; Figg WD; Annunziata CM
Cancer; 2016 Feb; 122(4):588-597. PubMed ID: 26566079
[TBL] [Abstract][Full Text] [Related]
14. Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer.
Friedlander M; Butow P; Stockler M; Gainford C; Martyn J; Oza A; Donovan HS; Miller B; King M
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S44-8. PubMed ID: 19955914
[TBL] [Abstract][Full Text] [Related]
15. Management of recurrent epithelial ovarian carcinoma.
Vasey PA
Aust N Z J Obstet Gynaecol; 2005 Aug; 45(4):269-77. PubMed ID: 16029291
[TBL] [Abstract][Full Text] [Related]
16. Investigational agents against platinum-resistant ovarian cancer.
Lorusso D; Ferrandina G; Fanfani F; Gagliardi ML; Scambia G
Expert Opin Investig Drugs; 2007 Mar; 16(3):325-36. PubMed ID: 17302527
[TBL] [Abstract][Full Text] [Related]
17. New horizons for platinum-resistant ovarian cancer: insights from the 2023 American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) Annual Meetings.
El Bairi K; Madariaga A; Trapani D; Al Jarroudi O; Afqir S
Int J Gynecol Cancer; 2024 May; 34(5):760-772. PubMed ID: 38101815
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors.
Petrillo M; Fagotti A; Ferrandina G; Fanfani F; Costantini B; Vizzielli G; Pedone Anchora L; Nero C; Margariti PA; Scambia G
Gynecol Oncol; 2013 Oct; 131(1):36-41. PubMed ID: 23791829
[TBL] [Abstract][Full Text] [Related]
19. Pursuit of optimum outcomes in ovarian cancer: methodological approaches to therapy.
Gibbs DD; Gore ME
Drugs; 2001; 61(8):1103-20. PubMed ID: 11465872
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer.
Nguyen TT; Wright JD; Powell MA; Gibb RK; Rader JS; Allsworth JE; Mutch DG
Int J Gynecol Cancer; 2008; 18(6):1194-9. PubMed ID: 18217964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
